Annexon Inc. (NASDAQ: ANNX) presented new clinical data on its investigational drug vonaprument at The Retina Society 59th Annual Scientific Meeting in Los Angeles, held September 23–26, 2026.
Vonaprument is an antigen-binding fragment designed to inhibit C1q, a molecule in the classical complement pathway, and is formulated for intravitreal administration. The drug has received Fast Track designation from the U.S. Food and Drug Administration and Priority Medicine designation from the European Medicines Agency.
Geographic atrophy is a neurodegenerative eye disease that gradually destroys central vision required for reading, driving, and recognizing faces. It affects more than 8 million people worldwide.
Data from the Phase 2 ARCHER Study was highlighted at the meeting. The trial evaluated vonaprument in patients with geographic atrophy administered through month 12. Dr. Mark Barakat of the Retina Macula Institute of Arizona presented on vision outcomes in eyes with subfoveal RPE lesions from the trial.
Dr. Ashkan Abbey of Texas Retina Associates presented baseline characteristics of the Phase 3 ARCHER II trial. The study enrolled 659 patients globally and uses a confirmed best corrected visual acuity loss of 15 letters or more as its primary endpoint, measured through months 15 and 24. Month 15 results from ARCHER II are expected in the fourth quarter of 2026.
